CD274 molecule

Overview

Programmed Death-Ligand 1 (PD-L1), also known as CD274, is a type I transmembrane glycoprotein that functions as an immune checkpoint ligand. It is expressed on the surface of antigen-presenting cells such as dendritic cells, on many tumour cells, and on stromal populations within the tumour microenvironment including cancer-associated fibroblasts. PD-L1 is also displayed on extracellular vesicles shed by both tumour and immune cells, a form in which it retains its inhibitory activity.

The protein exerts its effects by binding Programmed cell death 1 (PD-1) on activated T cells, delivering an inhibitory signal that dampens T cell proliferation, cytokine production, and cytotoxic T cell killing. This axis normally limits excessive immune activation and helps maintain peripheral tolerance, and regulatory T cells participate in the same restraint of effector responses. Tumours co-opt the pathway to escape immune surveillance, which makes PD-L1 both a marker of immune escape and a therapeutic target.

Blockade of the PD-1/PD-L1 axis is the basis of a major class of cancer immunotherapy. checkpoint inhibitor antibodies directed at PD-1 (pembrolizumab, nivolumab) or at PD-L1 itself (durvalumab) restore cytotoxic T cell activity against tumours, and PD-L1 expression measured by immunohistochemistry is used to help select patients in malignancies including lung cancer, head and neck squamous cell carcinoma, and others. The same axis contributes to T cell dysfunction in haematological settings such as multiple myeloma. Because these agents release a physiological brake on immunity, they carry characteristic immune-related adverse events, including inflammatory arthritis, myocarditis, myasthenia gravis, colitis, and endocrinopathies. PD-L1 is additionally being pursued beyond antibody blockade as a target for radioligand imaging and therapy and for targeted protein degradation strategies.

Recent Publications Summary (3 months)

Recent studies continued to position PD-L1 as both a therapeutic target and a mechanistic marker of immune escape across cancer and immunotherapy settings. In bladder cancer, ALG1 was shown to directly interact with PD-L1 and catalyze its glycosylation, stabilizing the protein by protecting it from ubiquitin-mediated proteasomal degradation and increasing cell-surface expression; this enhanced PD-1/PD-L1 signaling, promoted macrophage M2 polarization, and supported immune evasion 42168360May. In hepatocellular carcinoma, PRXL2B knockdown reduced AKT phosphorylation and PD-L1 expression and enhanced the antitumor effect of oncolytic adenovirus H101, linking PD-L1 to treatment response in a PI3K/AKT-associated axis 42161529May. In colorectal cancer, OVOL2 loss increased glycolysis, lactate production, histone lactylation at the CD274 promoter, and PD-L1 expression, contributing to CD8+ T-cell exhaustion; sulconazole reversed these changes by inhibiting glycolysis and reducing PD-L1 42252920Jun. RAD18 was also reported to promote immunosuppression through AKT/mTOR/c-Myc signaling and regulation of TGF-β1/PD-L1 expression, with high RAD18 associated with anti-PD-1 resistance 42115304May.

Several studies explored PD-L1-directed therapeutic engineering. A PD-L1-targeted radioligand/protein degradation platform combined PET imaging, targeted protein degradation, radiostimulation, and radioligand therapy in a single construct; [68Ga]Ga/[177Lu]Lu-DOTA-BLP showed specific tumor uptake in mice, and the radioligand increased DNA damage and PD-L1 expression to “prime” tumors for enhanced degradation 42372826Jun. A plug-and-play UPTAB degradation platform achieved near-complete degradation of PD-L1 in multiple cancer cell lines and enabled simultaneous degradation of EGFR/PD-L1 and other combinations 42138807May. Another bifunctional approach fused an anti-PD-L1 nanobody to carboxypeptidase G2 to combine checkpoint targeting with enzyme-mediated prodrug activation 42128116May. In extracellular vesicle-based strategies, removing PD-L1 from dendritic cell EVs strengthened antitumor immunity and immune-mediated tumor rejection in mice 42377985Jun, while a pH-responsive peptide system disrupted small EVs in the tumor microenvironment to prevent EV PD-L1 interactions with PD-1 on CD8+ T cells and restore effector function 42204141May. PET-guided EV delivery of siPD-L1 to lung metastases also enhanced tumor immune responses 42139331May.

PD-L1 was further implicated in resistance, immune modulation, and combination therapy. Neutrophils upregulated PD-L1 in response to immunotherapy, and this IFN-γ-dependent, cell-intrinsic response shaped whether neutrophils blocked or supported treatment 42296966Jun. A biomimetic nanoemulsion presenting PD-1 blocked tumor PD-L1 while co-delivering glucose- and lactate-depleting enzymes, thereby potentiating antitumor immunotherapy PMID 42266078. In another study, tumor-specific delivery of CD28 siRNA reduced cancer-cell CD28, lowered PD-L1 expression, and remodeled the tumor microenvironment to overcome anti-PD-1 resistance 42261788Jun. Trans-vaccenic acid-loaded lipid nanoparticle increased intratumoral TVA, reduced CD8+ T-cell exhaustion, downregulated PD-1, upregulated PD-L1, and potentiated PD-L1 blockade therapy in hot and cold tumor models 42261893Jun. In pancreatic cancer, stress-induced CXCL13/YAP/PD-L1 signaling supported senescent cell survival and tumor progression, and CXCL13 blockade suppressed tumor growth 42066078May.

Clinical and translational reports also highlighted PD-L1 as a biomarker in checkpoint inhibitor use. A case of cholangiocarcinoma treated with durvalumab developed immune-related myasthenia gravis and myocarditis, underscoring the toxicity profile of PD-L1 inhibition 42384108Jul. Another case report described a sustained response to durvalumab plus tremelimumab in primary hepatic undifferentiated carcinoma with high PD-L1 expression 42081075May. In advanced NSCLC, first-line pembrolizumab was evaluated in PD-L1-high disease in routine practice 42285782Jun, and a phase 3 interim analysis tested sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab alone in PD-L1-positive advanced NSCLC 42214392May. Additional studies reported that PD-L1 expression was associated with inferior outcomes in advanced NSCLC with uncommon EGFR mutations treated with second-generation EGFR-TKIs 42136330May, and that PD-L1-targeted assays and imaging approaches may improve EV phenotyping and treatment stratification 42296185Jun42083266May.

What Changes, What Holds

1. PD-L1 is being refined as a regulated immune-evasion node rather than a static marker
REINFORCES These studies sharpen the baseline view that CD274 supports tumour immune escape by showing additional upstream control points that increase PD-L1 abundance and signaling. The new work does not replace the PD-1/PD-L1 model; it extends it by linking PD-L1 stability and expression to glycosylation, metabolic rewiring, and AKT/mTOR-associated regulation in specific Cancers 42168360May42161529May. That makes PD-L1 more clearly a dynamic effector of resistance and a potential readout of treatment response.

2. PD-L1 can now be manipulated as a therapeutic payload, not only blocked as a checkpoint
NEW DIRECTION The Overview already notes imaging, therapy, and degradation strategies, and this paragraph expands that direction by showing increasingly integrated platforms that combine targeting, degradation, radiotherapy, and prodrug activation. It also extends the baseline beyond antibody blockade into extracellular vesicle engineering and local delivery of PD-L1-directed cargo. These are not contradictions, but they do broaden CD274 from a checkpoint ligand to a modular intervention target 42372826Jun42138807May.

3. PD-L1 remains a central resistance mechanism, but the new work shows it can be driven by broader metabolic and stromal programs
REINFORCES The baseline already frames PD-L1 as a tumour escape pathway and therapeutic target; these studies reinforce that role while adding mechanistic routes by which tumours and myeloid cells tune the axis during therapy. The important shift is not in direction but in context: glycolysis, lactylation, neutrophil state, and other microenvironmental programs can all feed into PD-L1-linked immune suppression and anti-PD-1 resistance 42296966Jun42115304May. That strengthens the case for combination strategies aimed upstream of CD274.

4. PD-L1 expression continues to function as a clinically useful biomarker, while PD-L1 blockade toxicity remains a real limiting factor
REINFORCES The Overview already states that PD-L1 guides patient selection and that PD-L1-directed therapy causes immune-related adverse events; this paragraph confirms both points in contemporary practice. It does not alter the established account, but it underscores that PD-L1-high disease still informs treatment choice and that durvalumab can produce serious immune toxicity in real-world use 42384108Jul42285782Jun. The added implication is practical: biomarker use and toxicity monitoring remain inseparable from PD-L1-directed therapy.